UK markets close in 2 hours 5 minutes
  • FTSE 100

    6,851.29
    -112.35 (-1.61%)
     
  • FTSE 250

    23,311.69
    -347.25 (-1.47%)
     
  • AIM

    1,253.40
    -22.34 (-1.75%)
     
  • GBP/EUR

    1.1674
    -0.0039 (-0.33%)
     
  • GBP/USD

    1.3675
    -0.0063 (-0.46%)
     
  • BTC-GBP

    31,949.16
    -2,850.46 (-8.19%)
     
  • CMC Crypto 200

    1,087.11
    -138.42 (-11.29%)
     
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • DOW

    34,584.88
    -166.42 (-0.48%)
     
  • CRUDE OIL

    70.87
    -1.10 (-1.53%)
     
  • GOLD FUTURES

    1,759.00
    +7.60 (+0.43%)
     
  • NIKKEI 225

    30,500.05
    +176.75 (+0.58%)
     
  • HANG SENG

    24,099.14
    -821.62 (-3.30%)
     
  • DAX

    15,074.73
    -415.44 (-2.68%)
     
  • CAC 40

    6,414.30
    -155.89 (-2.37%)
     

90,889 Orion Corporation A shares converted into B shares

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

ORION CORPORATION STOCK EXCHANGE RELEASE 14 SEPTEMBER 2021 at 9.00 EEST

90,889 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 90,889 A shares have been converted into 90,889 B shares. The conversion has been entered into the Trade Register on 14 September 2021.

The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 34,915,634 A shares and 106,218,644 B shares. The number of votes of the company's shares is after the conversion 804,531,324.

Orion Corporation

Jari Karlson

CFO

Olli Huotari

SVP, Corporate Functions


Contact person:
Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting